7AL Stock Overview A research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Alligator Bioscience AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Alligator Bioscience Historical stock prices Current Share Price SEK 0.0001 52 Week High SEK 0.13 52 Week Low SEK 0.0001 Beta 1.6 1 Month Change -99.38% 3 Month Change -99.81% 1 Year Change -99.90% 3 Year Change -99.96% 5 Year Change -99.99% Change since IPO -100.00%
Recent News & Updates
Alligator Bioscience AB (publ) Announces Positive Outcomes from adjusted Indirect Treatment Comparations Studies Jan 27
Alligator Bioscience Announces Positive Outcome of Regulatory Interactions on Phase 3 Cmc Activities Jan 16 Alligator Bioscience AB (publ) to Report Fiscal Year 2024 Results on Jan 22, 2025
Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527 Nov 12
Alligator Bioscience AB (publ), Annual General Meeting, May 07, 2025 Nov 01
Alligator Bioscience AB (Publ) Appoints Nomination Committee in Respect of AGM 2025 Oct 31 See more updates
Alligator Bioscience AB (publ) Announces Positive Outcomes from adjusted Indirect Treatment Comparations Studies Jan 27
Alligator Bioscience Announces Positive Outcome of Regulatory Interactions on Phase 3 Cmc Activities Jan 16 Alligator Bioscience AB (publ) to Report Fiscal Year 2024 Results on Jan 22, 2025
Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527 Nov 12
Alligator Bioscience AB (publ), Annual General Meeting, May 07, 2025 Nov 01
Alligator Bioscience AB (Publ) Appoints Nomination Committee in Respect of AGM 2025 Oct 31
Third quarter 2024 earnings released: kr0.08 loss per share (vs kr0.083 loss in 3Q 2023) Oct 25
Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study Sep 16
Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024 Sep 14
Second quarter 2024 earnings released: kr0.07 loss per share (vs kr0.19 loss in 2Q 2023) Jul 12 Alligator Bioscience AB (Publ) Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024 Jul 11
Alligator Bioscience Announces Completion of Enrollment in Mitazalimab Optimize-1 Study Jul 10
Alligator Bioscience Announces Results from the Ongoing Optimize-1 Trial Jun 26
Alligator Bioscience AB (publ) to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024 Jun 21
Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting May 24
Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer May 15 Alligator Bioscience AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024
High number of new directors May 08
Alligator Bioscience AB (Publ) Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board Apr 05
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4 Mar 07 Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation
Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer Jan 29
No longer forecast to breakeven Nov 22
Alligator Bioscience AB (Publ) Appoints Bertil Brinck as Chairman of the Nomination Committee Nov 07
New minor risk - Profitability Oct 30
Third quarter 2023 earnings released Oct 28
Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab Oct 13
Alligator Bioscience AB (publ) Announces Resignation of Malin Carlsson as Chief Operating Officer At the End of October Aug 18
Second quarter 2023 earnings released: kr0.19 loss per share (vs kr0.21 loss in 2Q 2022) Jul 14 Jul 14
Alligator Bioscience AB (Publ) Announces Executive Changes Jul 06 Alligator Bioscience AB (publ) Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist Jul 01
Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer Jun 27
Alligator Bioscience to Present Latest Clinical Data from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer At Asco Annual Meeting 2023 Jun 06 Apr 26
Full year 2022 earnings released Mar 29
No longer forecast to breakeven Feb 26 Alligator Bioscience AB (Publ) Announces Management Changes
Alligator Bioscience Promotes Laura Von Schantz to Chief Technology Officer Feb 14
Full year 2022 earnings released: kr0.88 loss per share (vs kr0.64 loss in FY 2021) Feb 12
Forecast to breakeven in 2024 Jan 03
Alligator Bioscience Announces Positive Interim Results from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate Jan 03
Alligator Bioscience Announces Publication Highlighting Phase 1 Mitazalimab Data in Solid Tumors in Peer-Reviewed Journal Dec 24
High number of new directors Nov 17
Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.43 loss in 3Q 2021) Oct 21
Alligator Bioscience Announces Positive Safety Data from 900 mg Dose Cohort in ATOR-1017 Phase 1 Dose Escalation Study in Patients with Advanced Solid Malignancies Oct 01
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND Sep 20
Alligator Bioscience Presents Additional Data from Mitazalimab OPTIMIZE-1 Phase 1B/2 Trial at AACR Special Conference on Pancreatic Cancer 2022 Sep 15
Second quarter 2022 earnings released: EPS: kr0.21 (vs kr0.41 loss in 2Q 2021) Jul 13 Alligator Bioscience AB (publ), Annual General Meeting, May 03, 2023
Alligator Bioscience AB (publ) Appoints Sumeet Ambarkhane as Its Chief Medical Officer Jul 08 Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022 May 31
Alligator Bioscience Expands Its Board of Directors with the Appointment of Staffan Encrantz and Denise Goode May 10
Less than half of directors are independent Apr 29
Alligator Bioscience AB (publ) Announces Completion of 600 Mg Dose Cohort for ATOR-1017, Dose-Escalation and Enrollment for 900 Mg Dose Cohort Commences Apr 03
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 12 Alligator Bioscience AB (publ) to Report Q3, 2022 Results on Oct 20, 2022
Alligator Bioscience Appoints Sumeet Ambarkhane as Chief Medical Officer Feb 01
Alligator Bioscience Announces Optimize-1 Trial Update Jan 18
Third quarter 2021 earnings released: kr0.43 loss per share (vs kr0.43 loss in 3Q 2020) Oct 22
Alligator Bioscience AB (Publ) Initiates A Phase II Trial with Mitazalimab, and Drug Candidate Ator-1017 Is Soon to Follow Jul 02
Alligator Bioscience AB and Scandion Oncology A/S Present Promising Preclinical Data Jun 30
Independent Director Kenth Petersson has left the company Jun 08
Independent Director Kirsten Drejer has left the company Jun 08
Independent Director Jonas Sjögren has left the company Jun 08
Independent Director Ulrika Danielsson has left the company Jun 08
Independent Chairman Peter Benson has left the company Jun 08
Alligator Bioscience Presents Positive Phase I Data At ASCO for Its 4-1BB Agonist Drug Candidate ATOR-1017 Jun 04
Independent Director recently bought €104k worth of stock May 01
Full year 2020 earnings released: kr2.01 loss per share (vs kr2.94 loss in FY 2019) Mar 21
Alligator Bioscience Appoints Søren Bregenholt as New CEO Mar 19
Alligator Bioscience to Develop Tumour-Directed Immunotherapies in Clinical Phase II Mar 18
Alligator Bioscience Presents New Preclinical Data At AACR Mar 12
Full year 2020 earnings released: kr2.01 loss per share (vs kr2.94 loss in FY 2019) Feb 27
Revenue beats expectations Feb 27 Alligator Bioscience AB (publ) to Report Q1, 2021 Results on Apr 27, 2021
Chief Medical Officer has left the company Feb 03
New 90-day low: €0.61 Jan 29
Alligator Bioscience AB (Publ) Appoints Peter Ellmark as Chief Scientific Officer Jan 15 Shareholder Returns 7AL DE Biotechs DE Market 7D -99.3% 1.0% 2.0% 1Y -99.9% -4.8% 15.2%
See full shareholder returns
Return vs Market: 7AL underperformed the German Market which returned 14.1% over the past year.
Price Volatility Is 7AL's price volatile compared to industry and market? 7AL volatility 7AL Average Weekly Movement 919.8% Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 7AL's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7AL's weekly volatility has increased from 451% to 920% over the past year.
About the Company Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company’s product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG
Show more Alligator Bioscience AB (publ) Fundamentals Summary How do Alligator Bioscience's earnings and revenue compare to its market cap? 7AL fundamental statistics Market cap €2.44m Earnings (TTM ) -€20.37m Revenue (TTM ) €5.03m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 7AL income statement (TTM ) Revenue SEK 57.72m Cost of Revenue SEK 167.21m Gross Profit -SEK 109.48m Other Expenses SEK 124.41m Earnings -SEK 233.89m
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 24, 2025
Earnings per share (EPS) -0.31 Gross Margin -189.67% Net Profit Margin -405.19% Debt/Equity Ratio 0%
How did 7AL perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/30 12:55 End of Day Share Price 2025/01/30 00:00 Earnings 2024/12/31 Annual Earnings 2024/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Alligator Bioscience AB (publ) is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ingrid Gafanhão Kempen & Co. NV Carl Ramanius Redeye
Show 0 more analysts 
